CABA · Cabaletta Bio, Inc. · Executive Compensation
$2.02
-0.06 (-2.88%)
At close · Oct 6
Return incl. dividend (before tax)
Going-concern doubt
— flagged Aug 13, 2026
Substantial doubt about the company's ability to continue as a going concern.
“we have concluded that substantial doubt exists about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Market Cap
$335.70M
Shares
169.55M
Volume · Oct 6
4.13M
Avg daily vol (3M)
4.86M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Scott Brun, M.D. | Chair of the NCG Committee | Appointed | 2023-07-24 |
| Mark Simon | Chair of the Compensation Committee | Appointed | 2023-07-24 |
| Mark Simon | Chair of the NCG Committee | Resigned | 2023-07-24 |
| Catherine Bollard, M.D. | Chair of the Compensation Committee | Resigned | 2023-07-24 |
| Shawn Tomasello | Board of Directors | Appointed | 2023-07-24 |
| Scott Brun, M.D. | Class I director | Appointed | 2023-06-01 |